Skip to Main Content

Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease, Eli Lilly issued a six-paragraph press release extolling the promise of an under-the-radar therapy of its own — one that, if effective, would seem to support Biogen’s claims as well. Now the world is about to see detailed data that will illuminate whether Lilly’s work offers reason for hope after years of frustration — or more equivocal evidence in the search for a treatment to slow the mental decline that marks Alzheimer’s.

Lilly will present the results of a small, Phase 2 study on its drug, donanemab, on March 13 at a virtual conference of Alzheimer’s researchers. Lilly said in January that the intravenous drug met its primary goal with a 32% improvement in cognition and function compared to placebo, a statistically significant difference, but researchers are reserving judgement until the company reveals key study details.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Is the March 13 presentation open, to public? If yes, how does one access or can participate? Can Damian find out? If he cannot or if the session is not open to the public, then what is the goal or purpose of his article?

Comments are closed.